Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer Ended

2025-521115-40-00 Advanced or Metastatic Non-small Cell Lung Cancer 4 2025-09-30
A Study to Test Inavolisib Treatments in Patients with Early-Stage, PIK3CA-Mutated Breast Cancer Ended

2024-518811-20-00 Early-Stage, PIK3CA-Mutated Breast Cancer (BC) 4 2025-09-30
An interventional, multicenter, and international phase 1/2, light-dose-escalation study to investigate the safety and feasibility of intrao… Ended

2025-520563-41-00 High-grade glioma Glioblastoma 7 2025-09-29
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLL… Ended

2024-520050-38-00 Extensive stage small cell lung cancer (ES-SCLC). 5 2025-09-18
Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM) Ended

2024-511452-40-00 Oncology - Glioblastoma (GBM) 10 2025-09-12
FTIH study to investigate the safety and preliminary efficacy of the DNA-repair inhibitor GSK4418959 alone or in combination with other anti… Ended

2024-519721-37-00 Neoplasms, Colorectal 7 2025-08-06
A Phase 1, Multicenter, Open-Label Study of REM-422, an MYB mRNA Degrader, in Patients With Relapsed/Refractory AML or Higher-Risk MDS Ended

2023-510479-72-00 Relapsed/Refractory AML or Higher-Risk MDS 3 2025-08-05
A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended

2024-519773-19-00 Gastroesophageal Junction Adenocarcinoma 5 2025-07-31
A trial to learn more about the effects of ribociclib taken with endocrine therapy in patients with early breast cancer. Ended

2022-503001-38-01 HR-positive HER-2- negative Breast Cancer 5 2025-07-08
A PHASE 1B, OPEN-LABEL, DOSE ESCALATION WITH AN EXPANSION TRIAL OF A IN COMBINATION WITH B OR A PLUS STANDARD OF CARE IN PATIENTS WITH XXX C… Ended

2025-521582-27-00 XXX CANCER ELIGIBLE FOR SECOND LINE TREATMENT 3 2025-07-03
A Phase 2, open-label study to evaluate the efficacy and safety of anitocabtagene autoleucel in participants with newly diagnosed multiple m… Ended

2024-517020-18-00 Newly diagnosed multiple myeloma according to IMWG cri 4 2025-06-30
A randomized active-controlled trial for vulvovaGinal atRophy in breAst Cancer patients on Endocrine therapy (GRACE-trial) Ended

2024-510845-33-00 Breast cancer patients on endocrine therapy (AI or SERM 6 2025-06-23
Phase 1b/2 Study of Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Participants With Advanced Gastric Cancer (Substudy GC) Ended

2024-517817-34-00 Gastric Cancer 9 2025-06-18
Evaluation of the safety and efficacy of the drug Veonetinib (AL8326) in the post-first treatment of small cell lung cancer, non small cell … Ended

2023-509067-24-01 - Small Cell Lung Cancer (SCLC) patients who need ≥2nd 4 2025-06-17
Study of Zelenectide Pevedotin in Participants with Advanced Breast Cancer Ended

2024-517868-33-00 NECTIN4 Amplified Advanced Breast Cancer 4 2025-06-12
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects with SCLC Ended

2024-516051-40-00 Small Cell Lung Cancer (SCLC) 4 2025-06-10
PLUG-IN. Phase 2 of pembrolizumab combined with enfortumab vedotin for advanced melanoma patients. Ended

2024-514163-26-00 Advanced Melanoma 4 2025-06-09
Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC) Ended

2024-517818-15-00 Non-Small Cell Lung Cancer 9 2025-06-06
A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients with Lung Fibr… Ended

2024-511754-41-00 idiopathic pulmonary fibrosis 4 2025-05-29
"Neoadjuvant phase II study of pembrolizumab and carboplatin plus paclitaxel for stage I triple-negative breast cancer (The TELESCOPE study)… Ended

2024-513511-27-00 HR-negative/HER2-negative resectable stage I TNBC. 4 2025-05-29
A study to test different doses of BI 1831169 alone and in combination with an anti-PD-1 antibody in people with different types of advanced… Ended

2024-512504-19-00 solid tumors 1 2025-05-28
Phase 2 Pan-Tumor Trial of R-DXd for Advanced/Metastatic Solid Tumors Ended

2024-513307-13-00 Advanced/metastatic solid tumors including gynecologica 4 2025-05-26
Dose escalation/expansion trial with BYON4228 alone and in combination in metastatic solid tumors Ended

2024-517952-37-00 Locally advanced or metastatic cancer (Solid tumors) 9 2025-05-22
First trial in humans testing the safety and efficacy of IMGN151 in women with recurrent gynaecological cancers Ended

2023-506842-22-00 Recurrent endometrial cancer, recurrent epithelial ovar 7 2025-05-19